These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8723306)

  • 1. Auditory sustained attention in schizophrenia: a comparison of the Continuous Performance Test and the Pigache Attention Task.
    Pigache RM
    Psychiatry Res; 1996 Mar; 60(2-3):155-65. PubMed ID: 8723306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine.
    Pigache RM
    Schizophr Res; 1993 Jun; 10(1):39-50. PubMed ID: 8369231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vigilance deficits in schizophrenics and affectively disturbed patients.
    Rund BR; Orbeck AL; Landrø NI
    Acta Psychiatr Scand; 1992 Sep; 86(3):207-12. PubMed ID: 1414414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained attention and positive formal thought disorder in schizophrenia.
    Pandurangi AK; Sax KW; Pelonero AL; Goldberg SC
    Schizophr Res; 1994 Sep; 13(2):109-16. PubMed ID: 7986767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients.
    Chen WJ; Liu SK; Chang CJ; Lien YJ; Chang YH; Hwu HG
    Am J Psychiatry; 1998 Sep; 155(9):1214-20. PubMed ID: 9734545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of illness duration on perceptual asymmetry in schizophrenia.
    Carr V; Wale J; Dewis S; Stephan L
    Schizophr Res; 1992 Sep; 7(3):211-6. PubMed ID: 1356424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of antipsychotic drugs and symptomatology on perceptual asymmetry in schizophrenia.
    Carr V; Wale J
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1531-7. PubMed ID: 2906089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of stimulus salience in CPT-AX performance of schizophrenia patients.
    Lee J; Park S
    Schizophr Res; 2006 Jan; 81(2-3):191-7. PubMed ID: 16226875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What determines continuous performance task performance?
    van den Bosch RJ; Rombouts RP; van Asma MJ
    Schizophr Bull; 1996; 22(4):643-51. PubMed ID: 8938918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication may be required for the development of automatic information processing in schizophrenia.
    Serper MR; Bergman RL; Harvey PD
    Psychiatry Res; 1990 Jun; 32(3):281-8. PubMed ID: 2388967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous performance test and schizophrenia: a test of stimulus-response compatibility, working memory, response readiness, or none of the above?
    Elvevåg B; Weinberger DR; Suter JC; Goldberg TE
    Am J Psychiatry; 2000 May; 157(5):772-80. PubMed ID: 10784471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bimodal response sensitivity and bias in a test of sustained attention contrasting patients with schizophrenia and bipolar disorder to normal comparison group.
    Baerwald JP; Tryon WW; Sandford J
    Arch Clin Neuropsychol; 2005 Jan; 20(1):17-32. PubMed ID: 15620812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study.
    Pigache RM
    Schizophr Res; 1993 Jun; 10(1):51-9. PubMed ID: 8369232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reaction time of the Continuous Performance Test is an endophenotypic marker for schizophrenia: a study of first-episode neuroleptic-naive schizophrenia, their non-psychotic first-degree relatives and healthy population controls.
    Wang Q; Chan R; Sun J; Yao J; Deng W; Sun X; Liu X; Sham PC; Ma X; Meng H; Murray RM; Collier DA; Li T
    Schizophr Res; 2007 Jan; 89(1-3):293-8. PubMed ID: 17055704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of the Continuous Performance Test among community samples.
    Chen WJ; Hsiao CK; Hsiao LL; Hwu HG
    Schizophr Bull; 1998; 24(1):163-74. PubMed ID: 9502554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention disorders in schizophrenia.
    Suwa H; Matsushima E; Ohta K; Mori K
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):249-56. PubMed ID: 15149289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective attention in schizophrenia: sparing and loss of executive control.
    Mathalon DH; Heinks T; Ford JM
    Am J Psychiatry; 2004 May; 161(5):872-81. PubMed ID: 15121653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normalizing the crossover effect: enhancement of cognitive attentional processing in schizophrenia.
    Rosenbaum G; Taylor MJ; Minasian GJ
    Psychiatry Res; 1997 Oct; 72(3):167-76. PubMed ID: 9406906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance.
    Earle-Boyer EA; Serper MR; Davidson M; Harvey PD
    Psychiatry Res; 1991 Apr; 37(1):47-56. PubMed ID: 1862161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vulnerability to schizophrenia. III: Importance and limits of the Identical Pairs Continuous Performance Test].
    Laurent A; Rochet T; D'Amato T; Anchisi AM; Daumal M; Favre P; Bougerol T; Dalery J
    Encephale; 2000; 26(2):48-55. PubMed ID: 10858916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.